Key facts
- This page summarizes Greg Pyszczymuka's Form 4 filing for AYTU BIOPHARMA, INC (AYTU).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Nov 2024, 19:23.
Greg Pyszczymuka - 06 Nov 2024 Form 4 Insider Report for AYTU BIOPHARMA, INC (AYTU)
- Reporting relationship
- Chief Commercial Officer
- Issuer ticker
- AYTU
- Reported as of
- 06 Nov 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Nov 2024, 19:23:40 UTC
- Prior SEC filing
- 02 Oct 2024
- Next SEC filing
- 02 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mark Oki as attorney-in-fact for Greg Pyszczymuka
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Greg Pyszczymuka filed Form 4 for AYTU BIOPHARMA, INC (AYTU) on 08 Nov 2024.
Change
- Previous filing in this sequence was filed on 02 Oct 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AYTU
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +7,000
- Change %
- Price
- $0.000000
- Shares after
- 7,000
- Date
- 06 Nov 2024
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 7,000
- Exercise price
- $1.84
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest as follows: 1/3 on November 6, 2025, with the remaining options vesting in 24 equal monthly installments beginning December 6, 2025.